- Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
[作者:Tam, CS; Kantarjian, H; Cortes, J; Lynn, A; Pierce, S; Zhou, LS; Keating, MJ; Thomas, DA; Verstovsek, S,期刊:Journal of clinical oncology, 页码:5587-5593 , 文章类型: Article,,卷期:2009年27-33]
- Purpose Current prognostic tools in myelofibrosis (MF) fail to identify patients at the highest risk of death and are limited by their applicability only to the time of diagnosis. We aimed to define an accelerated phase ...
- Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211
[作者:Yamaguchi, M; Tobinai, K; Oguchi, M; Ishizuka, N; Kobayashi, Y; Isobe, Y; Ishizawa, K; Maseki, N; Itoh, K; Usui, N; Wasada, I; Kinoshita, T; Ohshima, K; Matsuno, Y; Terauchi, T; Nawano, S; Ishikura, S; Kagami, Y; Hotta, T; Oshimi, K,期刊:Journal of clinical oncology, 页码:5594-5600 , 文章类型: Article,,卷期:2009年27-33]
- Purpose To explore a more effective treatment for localized nasal natural killer (NK)/T-cell lymphoma, we conducted a phase I/II study of concurrent chemoradiotherapy. Patients and Methods Treatments comprised concurrent...
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
[作者:Matulonis, UA; Berlin, S; Ivy, P; Tyburski, K; Krasner, C; Zarwan, C; Berkenblit, A; Campos, S; Horowitz, N; Cannistra, SA; Lee, H; Lee, J; Roche, M; Hill, M; Whalen, C; Sullivan, L; Tran, C; Humphreys, BD; Penson, RT,期刊:Journal of clinical oncology, 页码:5601-5606 , 文章类型: Article,,卷期:2009年27-33]
- Purpose Angiogenesis is important for epithelial ovarian cancer (EOC) growth, and blocking angiogenesis can lead to EOC regression. Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth fact...
- Evidence-Based Approach to the Introduction of Positron Emission Tomography in Ontario, Canada
[作者:Evans, WK; Laupacis, A; Gulenchyn, KY; Levin, L; Levine, M,期刊:Journal of clinical oncology, 页码:5607-5613 , 文章类型: Article,,卷期:2009年27-33]
- Purpose The uptake of new health care technologies is usually driven by industry promotion, physician interest, patient demand, and institutional ability to acquire the technology. The introduction of positron emission t...
- Targeted High-Resolution Ultrasound Is Not an Effective Substitute for Sentinel Lymph Node Biopsy in Patients With Primary Cutaneous Melanoma
[作者:Sanki, A; Uren, RF; Moncrieff, M; Tran, KL; Scolyer, RA; Lin, HY; Thompson, JF,期刊:Journal of clinical oncology, 页码:5614-5619 , 文章类型: Article,,卷期:2009年27-33]
- Purpose To reassess traditional ultrasound descriptors of sentinel lymph node (SLN) metastases, to determine the minimum cross-sectional area (CSA) of an SLN metastasis detectable by ultrasound (US), and to establish whe...
- Genetic Abnormalities of the EGFR Pathway in African American Patients With Non-Small-Cell Lung Cancer
[作者:Leidner, RS; Fu, PF; Clifford, B; Hamdan, A; Jin, C; Eisenberg, R; Boggon, TJ; Skokan, M; Franklin, WA; Cappuzzo, F; Hirsch, FR; Varella-Garcia, M; Halmos, B,期刊:Journal of clinical oncology, 页码:5620-5626 , 文章类型: Article,,卷期:2009年27-33]
- Purpose Previous studies in non-small-cell lung cancer (NSCLC) have demonstrated a wide variation in responsiveness to epidermal growth factor receptor (EGFR)-targeting agents and in genetic aberrancies of the EGFR pathw...
- Prospective Study of Prostate Tumor Angiogenesis and Cancer-Specific Mortality in the Health Professionals Follow-Up Study
[作者:Mucci, LA; Powolny, A; Giovannucci, E; Liao, ZM; Kenfield, SA; Shen, RL; Stampfer, MJ; Clinton, SK,期刊:Journal of clinical oncology, 页码:5627-5633 , 文章类型: Article,,卷期:2009年27-33]
- Purpose Tumor growth requires the development of independent vascular networks that are often primitive in morphology and function. We examined whether microvessel morphology contributes to the considerable biologic hete...
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy: Phase II-Results of EORTC Study 30986
[作者:De Santis, M; Bellmunt, J; Mead, G; Kerst, JM; Leahy, M; Maroto, P; Skoneczna, I; Marreaud, S; de Wit, R; Sylvester, R,期刊:Journal of clinical oncology, 页码:5634-5639 , 文章类型: Article,,卷期:2009年27-33]
- Purpose There is no standard treatment for patients with advanced urothelial cancer who are ineligible ("unfit") for cisplatin-based chemotherapy (CHT). To compare the activity and safety of two CHT combinations in this ...
- Magnetic Resonance Imaging Screening of the Contralateral Breast in Women With Newly Diagnosed Breast Cancer: Systematic Review and Meta-Analysis of Incremental Cancer Detection and Impact on Surgical Management
[作者:Brennan, ME; Houssami, N; Lord, S; Macaskill, P; Irwig, L; Dixon, JM; Warren, RML; Ciatto, S,期刊:Journal of clinical oncology, 页码:5640-5649 , 文章类型: Review,,卷期:2009年27-33]
- Purpose Preoperative magnetic resonance imaging (MRI) is increasingly used for staging women with breast cancer, including screening for occult contralateral cancer. This article is a review and meta-analysis of studies ...
- Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment
[作者:Philip, PA; Mooney, M; Jaffe, D; Eckhardt, G; Moore, M; Meropol, N; Emens, L; O'Reilly, E; Korc, M; Ellis, L; Benedetti, J; Rothenberg, M; Willett, C; Tempero, M; Lowy, A; Abbruzzese, J; Simeone, D; Hingorani, S; Berlin, J; Tepper, J,期刊:Journal of clinical oncology, 页码:5660-5669 , 文章类型: Article,,卷期:2009年27-33]
- Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality, despite significant improvements in diagnostic imaging and operative mortality rates. The 5-year survival rate remains less than 5%...
- Spontaneous Remission in a Patient With t(4;14) Translocation Multiple Myeloma
[作者:Puig, N; Trudel, S; Keats, JJ; Li, ZH; Braggio, E; Ahmann, GJ; Zeng, S; Fonseca, R; Kukreti, V,期刊:Journal of clinical oncology, 页码:E194-E197 , 文章类型: Article,,卷期:2009年27-33]
-
- Recognition of a New Chemotherapeutic Vesicant: Trabectedin (Ecteinascidin-743) Extravasation With Skin and Soft Tissue Damage
[作者:Theman, TA; Hartzell, TL; Sinha, I; Polson, K; Morgan, J; Demetri, GD; Orgill, DP; George, S,期刊:Journal of clinical oncology, 页码:E198-E200 , 文章类型: Article,,卷期:2009年27-33]
-
|